Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.66 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523671 | 1.00 | IL6ST (0.66) | IL6STNAAAIDH1ALDH1A1GLA | |
| SCHEMBL475582 | 0.87 | NAAA (0.58) | IL6STNAAAIDH1STAT3FAAH | |
| SCHEMBL475580 | 0.87 | NAAA (0.58) | IL6STNAAAIDH1STAT3FAAH | |
| SCHEMBL7280995 | 0.87 | NAAA (0.58) | IL6STNAAAIDH1STAT3FAAH | |
| SCHEMBL4767695 | 0.87 | IL6ST (0.52) | IL6STIDH1ALDH1A1HPGDPIK3CD | |
| SCHEMBL19183081 | 0.87 | IL6ST (0.52) | IL6STNAAAIDH1ALDH1A1PIK3CD | |
| SCHEMBL4775861 | 0.87 | IL6ST (0.52) | IL6STNAAAIDH1ALDH1A1PIK3CD | |
| SCHEMBL8225610 | 0.87 | IL6ST (0.52) | IL6STIDH1ALDH1A1HPGDPIK3CD | |
| SCHEMBL4770816 | 0.87 | IL6ST (0.52) | IL6STIDH1ALDH1A1HPGDPIK3CD | |
| SCHEMBL4767686 | 0.87 | IL6ST (0.52) | IL6STNAAAIDH1ALDH1A1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | IL6ST 3901/4885NAAA 6/4885IDH1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.